The Drug Controller General of India said in June that remdesivir could be included in the clinical management protocol for Covid-19 as an experimental therapy for restricted emergency use on patients.
According to the National Pharmaceutical Pricing Authority, remdesivir has not been notified as a drug and hence it cannot regulate the price of one of the most expensive Covid-19 treatments in India.
The NPPA can only control prices of devices and products that are defined as drugs under the Drugs and Cosmetics Act. A product or device that is not notified as a drug goes out of the NPPA’s purview, people aware of the matter told ET.
In the case of stents and orthopaedic implants too, the government had to notify them as drugs to bring them under price regulation.
The DCGI said remdesivir cannot be brought within the ambit of a drug as yet.